使用阿特珠单抗和贝伐单抗治疗的肝细胞癌合并胃腺癌
Hepatocellular carcinoma with gastric adenocarcinoma treated with atezolizumab and bevacizumab.
作者信息
Suga Takayoshi, Kimura Yuko, Furuya Kensuke, Sato Hiroko
机构信息
Department of Gastroenterology Shibukawa Medical Center, National Hospital Organization Shibukawa Gunma Japan.
Department of Gastroenterology and Hepatology Gunma University Graduate School of Medicine Maebashi Gunma Japan.
出版信息
Clin Case Rep. 2023 Sep 7;11(9):e7875. doi: 10.1002/ccr3.7875. eCollection 2023 Sep.
Abstract
Atezolizumab and bevacizumab combination therapy might be one of the treatment options for hepatocellular carcinoma concurrent with gastric adenocarcinoma.
摘要
阿替利珠单抗和贝伐单抗联合治疗可能是肝细胞癌合并胃腺癌的治疗选择之一。
相似文献
1
Hepatocellular carcinoma with gastric adenocarcinoma treated with atezolizumab and bevacizumab.使用阿特珠单抗和贝伐单抗治疗的肝细胞癌合并胃腺癌
Clin Case Rep. 2023 Sep 7;11(9):e7875. doi: 10.1002/ccr3.7875. eCollection 2023 Sep.
2
Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies.阿替利珠单抗联合贝伐珠单抗治疗肝细胞癌：作用机制、药代动力学及未来治疗策略。
Future Oncol. 2021 Jun;17(17):2243-2256. doi: 10.2217/fon-2020-1290. Epub 2021 Mar 5.
3
Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).评估端粒酶衍生的 CD4 Th1 诱导性癌症疫苗联合 atezolizumab 加 bevacizumab 在不可切除肝细胞癌中的应用价值：一项随机非对照 II 期研究（TERTIO-PRODIGE 82）。
BMC Cancer. 2023 Jul 29;23(1):710. doi: 10.1186/s12885-023-11065-0.
4
Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.阿替利珠单抗联合或不联合贝伐珠单抗治疗不可切除肝细胞癌（GO30140）：一项开放标签、多中心、1b 期研究。
Lancet Oncol. 2020 Jun;21(6):808-820. doi: 10.1016/S1470-2045(20)30156-X.
5
Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma.晚期肝细胞癌中PD-1/PD-L1抗体与VEGF抑制剂联合免疫治疗的科学依据
Cancers (Basel). 2020 Apr 27;12(5):1089. doi: 10.3390/cancers12051089.
6
Atezolizumab plus bevacizumab versus sorafenib or atezolizumab alone for unresectable hepatocellular carcinoma: A systematic review.阿替利珠单抗联合贝伐单抗对比索拉非尼或单用阿替利珠单抗治疗不可切除肝细胞癌的系统评价
World J Gastrointest Oncol. 2021 Nov 15;13(11):1813-1832. doi: 10.4251/wjgo.v13.i11.1813.
7
Changes in Serum Growth Factors during Resistance to Atezolizumab Plus Bevacizumab Treatment in Patients with Unresectable Hepatocellular Carcinoma.不可切除肝细胞癌患者在接受阿替利珠单抗联合贝伐单抗治疗耐药期间血清生长因子的变化
Cancers (Basel). 2023 Jan 18;15(3):593. doi: 10.3390/cancers15030593.
8
Atezolizumab and bevacizumab-induced encephalitis in advanced hepatocellular carcinoma: Case report and literature review.阿替利珠单抗和贝伐珠单抗治疗晚期肝细胞癌致脑炎：病例报告及文献复习。
Medicine (Baltimore). 2021 Jun 18;100(24):e26377. doi: 10.1097/MD.0000000000026377.
9
Three cases of immune-related hypopituitarism after atezolizumab-bevacizumab treatment for hepatocellular carcinoma.三例肝癌患者在接受阿替利珠单抗联合贝伐珠单抗治疗后出现免疫相关性垂体功能减退症。
Clin J Gastroenterol. 2023 Jun;16(3):422-431. doi: 10.1007/s12328-023-01775-0. Epub 2023 Feb 23.
10
Final Overall Survival and Molecular Analysis in IMmotion151, a Phase 3 Trial Comparing Atezolizumab Plus Bevacizumab vs Sunitinib in Patients With Previously Untreated Metastatic Renal Cell Carcinoma.在 IMmotion151 研究中比较阿替利珠单抗联合贝伐珠单抗与舒尼替尼用于未经治疗的转移性肾细胞癌患者的最终总生存和分子分析。
JAMA Oncol. 2022 Feb 1;8(2):275-280. doi: 10.1001/jamaoncol.2021.5981.
引用本文的文献
1
Differential Gene Expression of Checkpoint Markers and Cancer Markers in Mouse Models of Spontaneous Chronic Colitis.自发慢性结肠炎小鼠模型中检查点标志物和癌症标志物的差异基因表达
Cancers (Basel). 2023 Sep 29;15(19):4793. doi: 10.3390/cancers15194793.
本文引用的文献
1
Immunotherapy in Gastric Cancer.胃癌的免疫治疗。
Curr Oncol. 2022 Mar 2;29(3):1559-1574. doi: 10.3390/curroncol29030131.
2
Immunotherapy of gastric cancer: Past, future perspective and challenges.胃癌的免疫治疗：过去、未来的展望与挑战。
Pathol Res Pract. 2021 Feb;218:153322. doi: 10.1016/j.prp.2020.153322. Epub 2020 Dec 24.
3
Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.阿替利珠单抗联合贝伐珠单抗治疗不可切除肝细胞癌。
N Engl J Med. 2020 May 14;382(20):1894-1905. doi: 10.1056/NEJMoa1915745.
4
Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study.贝伐珠单抗联合化疗作为晚期胃癌一线治疗：一项随机、双盲、安慰剂对照的 III 期研究。
J Clin Oncol. 2011 Oct 20;29(30):3968-76. doi: 10.1200/JCO.2011.36.2236. Epub 2011 Aug 15.
Zotero 插件